AbbVie reports revenue up 10.3% and raises its adjusted earnings guidance

AbbVie said third-quarter net revenues rose 10.3% on a reported basis to $17.404 billion. Diluted earnings per share were $2.37 on a GAAP basis and $3.82 on an adjusted (non-GAAP) basis. On a reported basis, Skyrizi net revenues rose 22.7% to $5.776 billion and Rinvoq 23.9% to $2.706 billion, while Humira fell 31.2% to $683 million. AbbVie raised its 2026 adjusted diluted EPS guidance range from $13.76–$13.96 to $13.95–$13.99 and announced a 5.2% dividend increase for 2027.